In the past few decades, studies in the field of cancer immunotherapy have been mainly focused on CTLA-4 and PD-1/PD-L1 blockade, However, since the complex interactions between tumor immune modulators, targeting PD-1/PDL-1 alone might be insufficient. The gene discussed is CTLA4; the disease is cancer.